• Disease Team Leader, CTIS, UH Cleveland Medical Center
  • Director, Novel Cell Therapy, UH Cleveland Medical Center
  • Professor, Medicine, CWRU School of Medicine


  • Gender: Male
  • Online Personal Health Record Available


Hillard M. Lazarus, MD, is a doctor of Hematology-Oncology at University Hospitals Cleveland Medical Center and a tenured full Professor of Medicine at Case Western Reserve University. He is the George & Edith Richman Professor & Distinguished Scientist in Cancer Research. He also is Disease Team Leader, CTIS, UH Cleveland Medical Center and Director, Novel Cell Therapy, UH Cleveland Medical Center. He was Director of the Blood and Marrow Transplant Program for more than 25 years.

Dr. Lazarus led a sustained and innovative clinical and translational research program focused on chemotherapy-dose escalation and blood and marrow transplantation for improving therapy of malignant disorders. His seminal impact in multiple aspects of transplantation was recognized in 1986 by his invitation to develop and chair the Blood and Marrow Transplant Committee of the National Cancer Institute-funded Eastern Cooperative Oncology Group (ECOG), a position he held until 2003.

From 1992 until 2010, Dr. Lazarus was Co-Chair of the Lymphoma Committee of the Center for International Blood and Marrow Transplantation Research (CIBMTR). For the past decade, he has been the Principal Investigator of the Case Consortium of the Blood & Marrow Transplant Clinical Trials Network (BMT CTN), an organization funded by the National Cancer Institute and the National Heart, Lung and Blood Institute. These groups provide national leadership in the development of new clinical trials for blood and marrow transplantation for the treatment of leukemia, lymphoma, myeloma and aplastic anemia.

Dr. Lazarus is internationally recognized for his contributions in the areas of mesenchymal stem cell transplantation, autologous blood and marrow transplantation for lymphoma, and allogeneic blood and marrow transplantation for malignancies; these efforts included the development of many new anti-cancer therapies and sophisticated supportive care technologies. He has been identified as an Outstanding Physician in many regional and national surveys and he was inducted into the Cancer Care Hall of Fame, American Cancer Society (North Regional Office) as well as receiving the American Cancer Society Lifetime Achievement Research Award (“The Standing Tall Tribute”).

Dr. Lazarus was awarded the Alumni Distinguished Service Award by Carnegie Mellon University where he also serves on the Deans Council. He currently is Chair of the Cancer Institutional Review Board (IRB) for Human Investigation at Case Western Reserve University and he serves on the American Society of Hematology Committee on Government Affairs. He has over 500 publications, including nearly 400 original publications in peer-reviewed journals, 54 book chapters and nearly 100 review articles. He is a member of several journal editorial boards and is the Editor-in-Chief of both Bone Marrow Transplantation as well as Blood Reviews.

Dr. Lazarus also is an editor of 7 textbooks in the field of blood and bone marrow transplantation, hematologic malignancies, and supportive care for cancer patients. He has been a gifted teacher and mentor to countless Medical Residents, Fellows and Junior Faculty, influencing many to pursue careers in academic medicine including hematopoietic cell transplantation.

Dr. Lazarus completed his undergraduate work at Carnegie Mellon University, Pittsburgh, Pennsylvania, and earned his medical degree from University of Rochester, Rochester, New York.

Board Certifications

American Board of Internal Medicine - Hematology
American Board of Internal Medicine - Internal Medicine
American Board of Internal Medicine - Medical Oncology

Education & Training


1970, Carnegie Mellon University

Medical / Professional School(s)

1974, University of Rochester School of Medicine and Dentistry


1975, Internal Medicine - University Hospitals of Cleveland


1977, Internal Medicine - University Hospitals of Cleveland


1979, Hematology/Oncology - University Hospitals of Cleveland


Lymphoma, Allogenic and Autologous Blood and Bone Marrow Transplantation, Therapy for Refractory Malignancies, Leukemia, Malignant Hematology, Multiple Myeloma

Awards & Recognition

  • Alumni Distinguished Service Award by Carnegie Mellon University
  • Cancer Care Hall of Fame, American Cancer Society (North Regional Office)
  • American Cancer Society Lifetime Achievement Research Award (“The Standing Tall Tribute”)
  • Honorary Alumnus of the Year Award, Case Western Reserve University School of Medicine
  • Hematology-Oncology Faculty Award for Excellence in Fellow Education
  • Leukemia & Lymphoma Society Man of the Year (Northern Ohio)

Office Locations

UH Cleveland Medical Center
Department of Medicine-Hematology and Oncology
11100 Euclid Ave
Cleveland, OH 44106
Get Directions

Research Interests

Development/enhancement of novel treatments for both malignant and non-malignant disorders using conventional and innovative approaches including hematopoietic cell transplantation (HCT) and cellular therapy for regenerative medicine.

Patient Satisfaction Reviews

About Our Survey

At University Hospitals, we believe in providing patients with all the information they need to make educated decisions about their health care and to choose the right doctor to meet their needs. That is why we partner with the independent patient satisfaction company Press Ganey to survey patients about their experiences at UH facilities and with UH physicians. We hold ourselves to the highest standards of care and are dedicated to creating a positive patient experience for every individual who sees a UH doctor.

Learn More

Patient Comments

There are no comments for this practitioner.

Industry Relationships

University Hospitals is committed to transparency in our interactions with industry partners, such as pharmaceutical, biotech, or medical device companies. At UH, we disclose practitioner and their family members’ ownership and intellectual property rights that are or in the process of being commercialized. In addition, we disclose payments to employed practitioners of $5,000 or more from companies with which the practitioners interact as part of their professional activities. These practitioner-industry relationships assist in developing new drugs, devices and therapies and in providing medical education aimed at improving quality of care and enhancing clinical outcomes. At the same time, UH understands that these relationships may create a conflict of interest. In providing this information, UH desires to assist patients in talking with their practitioners about industry relationships and how those relationships may impact their medical care.

UH practitioners seek advance approval for certain new industry relationships. In addition, practitioners report their industry relationships and activities, as well as those of their immediate family members, to the UH Office of Outside Interests annually. We review these reports and implement management plans, as appropriate, to address conflicts of interest that may arise in connection with medical research, clinical care and purchasing decisions.

View UH’s policy (PDF) on practitioner-industry relationships.

As of December 31, 2015, Hillard Lazarus, MD disclosed the following Outside Relationships with Industry:

Bristol Myers Squibb - Honoraria

Celgene Corp. - Honoraria

There is no publicly available rating for this medical professional because he or she either does not see patients or has not yet received the minimum number of Patient Satisfaction Reviews. To be eligible for display, we require a minimum of 30 surveys. This ensures that the rating is statistically reliable and a true reflection of patient satisfaction.